News

ALK Australia and TOGA Announce Partnership in New Grant for ALK+ Research

ALK Positive Australia Inc. and the Thoracic Oncology Group of Australia (TOGA) are honoured to announce a new grant partnership dedicated to advancing ALK+ NSCLC research in Australia for 2025!

The ALK Positive Australia and TOGA Inspirational Research Grant for ALK+ NSCLC aims to empower researchers with the resources they need to make a real difference in the lives of Australian people battling ALK+ NSCLC.

Lung cancer remains the leading cause of cancer deaths, yet less than 6% of research funding focuses on thoracic cancers, and even fewer would be specific for ALK+ NSCLC. This partnership bridges that gap, creating more opportunities for successful research and clinical trials that bring life-saving treatments and world-class care closer to ALK+ NSCLC patients.

TOGA’s Inspirational Grant Program, established in 2024, has already awarded five $50,000 grants to support vital research efforts. Now, with ALK Positive Australia joining forces, this program’s impact will be even greater.

“We are delighted to partner with ALK Positive Australia and the community of people living with ALK+ NSCLC to advance research in this rare type of lung cancer. Specific funding will encourage researchers to study this disease, and the incorporation of both expert scientific review and review by consumer representatives in our grant assessment process ensures the successfully funded research is both excellent quality and relevant to the community that has raised the funds and will benefit from the findings”

– Dr Megan Sanders, Executive Officer of TOGA

ALK Positive Australia, founded by patients and caregivers, understands the unique challenges faced by the ALK+ community. Their mission is to connect, educate, and empower patients and their care teams.

“Research equals hope for ALK+ lung cancer patients. ALK Positive Australia, founded in 2023 by patients and their care givers, is dedicated to funding research to enhance treatment options, life expectancy and quality of life for those affected by ALK+ lung cancer. Our ultimate goal is to find a cure. Partnering with the Thoracic Oncology Group of Australia (TOGA) brings invaluable medical and scientific expertise, ensuring that we support world-leading research right here in Australia.”

– Dr Jon Graftdyk, Chairperson at ALK Positive Australia

Applications for the 2025 ALK Positive Australia and TOGA Inspirational Research Grant for ALK+ NSCLC will open in August along with the other TOGA Inspirational Research Grants. Stay tuned for more information on how to submit your project.

Together, we can make a significant impact on the lives of Australians living with ALK+ NSCLC. Let’s spark change!

Share this

Facebook
Twitter
LinkedIn
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies target two pathways at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
The Thoracic Oncology Group of Australasia (TOGA) is thrilled to announce the recipients of the 2026 Inspirational Research Grants.
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
Why doesn’t immunotherapy work for all lung cancer patients? This article breaks down T-cell resistance mechanisms and what clinical trials are doing to overcome them.
Precision medicine has revolutionised lung cancer treatment by matching therapies to a patient’s genetic profile. Learn more.....
On May 2, 2023, the Australian Government announced a significant investment of $263.8 million over four years to establish the national Lung Cancer Screening Program
Explore the research behind lung cancer vaccines, including mRNA and personalised approaches. Understand the potential for prevention and treatment, plus the latest clinical trial updates.
The Thoracic Oncology Group of Australasia (TOGA) is thrilled to announce the recipients of the 2025 Inspirational Research Grants.
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
We’ve all seen the exciting ‘practice-changing’ results presented at conferences like ESMO 2023. But how do these new cancer treatments become available for everyday use
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
We’ve all seen the exciting ‘practice-changing’ results presented at conferences like ESMO 2023. But how do these new cancer treatments become available for everyday use